Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Aytu Biopharma (AYTU) over the last 13 years, with Q4 2025 value amounting to $738000.0.

  • Aytu Biopharma's Other Non-Current Assets fell 5151.12% to $738000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $738000.0, marking a year-over-year decrease of 5151.12%. This contributed to the annual value of $1.2 million for FY2025, which is 4489.7% down from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Other Non-Current Assets is $738000.0, which was down 5151.12% from $939000.0 recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Other Non-Current Assets peaked at $2.5 million during Q2 2023, and registered a low of $164954.0 during Q1 2021.
  • For the 5-year period, Aytu Biopharma's Other Non-Current Assets averaged around $1.0 million, with its median value being $859000.0 (2022).
  • Over the last 5 years, Aytu Biopharma's Other Non-Current Assets had its largest YoY gain of 275215.0% in 2021, and its largest YoY loss of 9709.7% in 2021.
  • Quarter analysis of 5 years shows Aytu Biopharma's Other Non-Current Assets stood at $457000.0 in 2021, then soared by 79.65% to $821000.0 in 2022, then increased by 10.48% to $907000.0 in 2023, then skyrocketed by 67.81% to $1.5 million in 2024, then plummeted by 51.51% to $738000.0 in 2025.
  • Its Other Non-Current Assets stands at $738000.0 for Q4 2025, versus $939000.0 for Q3 2025 and $1.2 million for Q2 2025.